Russia allowed the third phase of testing of the Korean drug from COVID-19

The Russian Ministry of HEALTH has allowed the third phase of testing of the South Korean drug for CORONAVIRUS Nafabelltan, follows from the data of the state register of medicines.

The start date of the trials is December 17, 2021, they will last until the end of September 2023, the drug was produced by Chong Kun Dang Pharmaceutical Corp. The purpose of the studies is "to evaluate the efficacy and safety of CKD-314 in patients hospitalized with covid-19," according to the registry.

Currently, Nafabelltan is used as a blood anticoagulant and for the treatment of acute pancreatitis. According to the developer, the drug showed effectiveness in fighting the infection when it was administered to COVID-19 patients with severe pneumonia, reported the Korean agency Yonhap.

At the end of September, the company received permission from the Ukrainian Ministry of Food and Drug Safety to conduct the third phase of clinical trials of Nafabelltan. To do this, the developer will conduct double-blind studies in which 600 patients with coronavirus and at a high risk of severe disease will take part. According to The Korea Herald, Chong Kun Dang Pharmaceutical Corp. also intends to obtain permits to conduct research in Brazil, Thailand, Argentina and Peru.